Making a case “for” focal therapy of the prostate in intermediate risk prostate cancer: current perspective and ongoing trials

被引：0

作者：

Alex Z. Wang

Amir H. Lebastchi

Luke P. O’Connor

Michael Ahdoot

Sherif Mehralivand

Nitin Yerram

Samir S. Taneja

Arvin K. George

Rafael Sanchez-Salas

John F. Ward

Pilar Laguna

Jean de la Rosette

Peter A. Pinto

机构：

[1] Urologic Oncology Branch,Division of Urologic Oncology, Department of Urology

[2] National Cancer Institute,Department of Urology

[3] National Institutes of Health,Department of Urology

[4] Molecular Imaging Branch,Department of Urology

[5] National Cancer Institute,Department of Urology

[6] National Institutes of Health,undefined

[7] NYU Langone Health,undefined

[8] NYU School of Medicine,undefined

[9] Michigan Medicine,undefined

[10] Institut Mutualiste Montsouris and Université Paris Descartes,undefined

[11] The University of Texas MD Anderson Cancer Center,undefined

[12] Istanbul Medipol University,undefined

来源：

World Journal of Urology | 2021年 / 39卷

关键词：

Focal therapy; prostate cancer; MRI;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Focal therapy is growing as an alternative management options for men with clinically localized prostate cancer. Parallel to the increasing popularity of active surveillance (AS) as a treatment for low-risk disease, there has been an increased interest towards providing focal therapy for patients with intermediate-risk disease. Focal therapy can act as a logical “middle ground” in patients who seek treatment while minimizing potential side effects of definitive whole-gland treatment. The aim of the current review is to define the rationale of focal therapy in patients with intermediate-risk prostate cancer and highlight the importance of patient selection in focal therapy candidacy.

引用

页码：729 / 739

页数：10